Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction

Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction

Sundra, T. Kelty, E. Rossi, G. Rendle, D. 2024 Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction

Front. Vet. Sci., 06 March 2024 Sec. Veterinary Pharmacology and Toxicology
Volume 11 – 2024 | https://doi.org/10.3389/fvets.2024.1332337

Frontiers | Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction (frontiersin.org)

Read more

Pharmacokinetics and Bioequivalance of Five Commercially Available Formulations of Omeprazole: A Preliminary Report.

Pharmacokinetics and Bioequivalance of Five Commercially Available Formulations of Omeprazole: A Preliminary Report.

Sykes, B. W., C. Underwood and P. C. Mills (2014). “Pharmacokinetics and Bioequivalance of Five Commercially Available Formulations of Omeprazole: A Preliminary Report.” Equine Veterinary Journal46(S47): 22-22.

Pharmacokinetics and Bioequivalance of Five Commercially Available Formulations of Omeprazole: A Preliminary Report – Sykes – 2014 – Equine Veterinary Journal – Wiley Online Library

Read more

The effect of formulation and feeding on the pharmacokinetics of doxycycline in the horse.

The effect of formulation and feeding on the pharmacokinetics of doxycycline in the horse.

Sykes, B. W., S. Higgins and G. D. Hallowell (2019). “The effect of formulation and feeding on the pharmacokinetics of doxycycline in the horse.” Equine Veterinary Journal51(S53): 28-28.

The effect of formulation and feeding on the pharmacokinetics of doxycycline in the horse – 2019 – Equine Veterinary Journal – Wiley Online Library

Read more

Five- versus seven-day dosing intervals of extended-release injectable omeprazole in the treatment of equine squamous and glandular gastric disease

Five- versus seven-day dosing intervals of extended-release injectable omeprazole in the treatment of equine squamous and glandular gastric disease

Sundra, T., E. Kelty and D. Rendle (2023). “Five- versus seven-day dosing intervals of extended-release injectable omeprazole in the treatment of equine squamous and glandular gastric disease.” Equine Vet J.

Five- versus seven-day dosing intervals of extended-release injectable omeprazole in the treatment of equine squamous and glandular gastric disease – PubMed (nih.gov)

Read more

Efficacy of long-acting injectable omeprazole (LAIOMEP) in the management of equine glandular gastric disease (EGGD) and equine squamous gastric disease (ESGD).

Efficacy of long-acting injectable omeprazole (LAIOMEP) in the management of equine glandular gastric disease (EGGD) and equine squamous gastric disease (ESGD).

Rendle, D. I., L. Gosling, A. Platt and A. Duff (2018). “Efficacy of long-acting injectable omeprazole (LAIOMEP) in the management of equine glandular gastric disease (EGGD) and equine squamous gastric disease (ESGD).” Equine Veterinary Journal50(S52): 14-14.

Read more